19
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs?

, , , , &
Pages 281-286 | Received 12 Mar 2004, Accepted 12 Feb 2004, Published online: 12 Jul 2009
 

Abstract

Drug use by injection can cause problems specific to this form of administration. Problems include an increased risk of drug overdose, drug dependence, the transmission of HIV, hepatitis B and hepatitis C and vein damage. Shifting drug injectors from injecting to another route of administration may minimize these problems. The aims of the study were to develop and trial an intervention to assist willing injecting drug users (IDUs) to shift to non-injecting routes of administration (NIROA) and to explore the acceptability and practicality of facilitating NIROA. IDUs were assessed and suitable subjects entered a cognitive behavioural trial consisting of five 1-hour sessions of individual therapy with a registered psychologist. Forty-two subjects were assessed (22 males and 20 females). Thirty subjects entered treatment. The mean age was 36 years. Twenty-one subjects were followed-up at 3 months and 10 subjects at 6 months. At 3 and 6 months, the proportion of subjects who had commenced using NIROA was 30% and 50%, respectively. This pilot study showed that it was possible to assist a minority of drug injectors to move from injecting to the non-injecting administration of drugs. However, many of these appeared to be already motivated to cease using drugs and adopting NIROA was one way of assisting this. Poor follow-up rate, lack of control group, questions about cost-effectiveness and the impact of market factors which possibly constrain shifting to NIROA suggest that further research is needed before it could be said that NIROA should be recommended as a viable harm reduction strategy in the Australian context. [Dolan K, Clement N, Rouen D, Rees V, Shearer J, Wodak A. Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? Drug Alcohol Rev 2004;23:281–286]

Kate Dolan PhD, Senior Lecturer National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, Nicole Clement MPsych (Clinical), Clinical Psychologist, National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, David Rouen MPsych (Clinical), Psych Clinical Psychologist, National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, Vaughan Rees PhD, Senior Research Officer, National Drug and Alcohol Research Centre, Sydney, Australia, James Shearer BA, Research Officer, National Drug and Alcohol Research Centre, Sydney, Australia, Alex Wodak FRACP, Director Alcohol and Drug Services, St Vincent's Hospital, Australia.

Kate Dolan PhD, Senior Lecturer National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, Nicole Clement MPsych (Clinical), Clinical Psychologist, National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, David Rouen MPsych (Clinical), Psych Clinical Psychologist, National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, Vaughan Rees PhD, Senior Research Officer, National Drug and Alcohol Research Centre, Sydney, Australia, James Shearer BA, Research Officer, National Drug and Alcohol Research Centre, Sydney, Australia, Alex Wodak FRACP, Director Alcohol and Drug Services, St Vincent's Hospital, Australia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.